Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250

Clinical Cancer Research

Volumn 5, Issue 10 SUPPL., 1999, Pages

  Steffens, Martijn G ^b   Boerman, Otto C ^a   De Mulder, Pieter H M ^b   Oyen, Wim J G ^b   Buijs, Wil C A M ^b   Witjes, J Alfred ^b   Van Den Broek, Wim J M ^b   Oosterwijk Wakka, Jeannette C ^b   Debruyne, Frans M J ^b   Corstens, Frans H M ^b   Oosterwijk, Egbert ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G 250 I 131; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY RESPONSE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOSCINTIGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; MALE; METASTASIS; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IODINE RADIOISOTOPES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RADIOIMMUNOTHERAPY; RECOMBINANT FUSION PROTEINS;

EID: 0032694512     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Boring, C. C., Squires, T. S., Tong, T., and Montgomery, S. Cancer statistics. CA Cancer J. Clin., 44: 7-26, 1994.
2. DeKernion, J. B. Renal tumors. In: P. C. Walsh, R. F. Gittes, A. D. Perlmutter, and T. A. Stamey (eds.). Campbell's Urology. 6th Ed., pp. 1294-1342. Philadelphia, PA: W. B. Saunders, 1993.
3. Mulders, P., Figlin, R., deKernion, J. B., Wiltrout, R., Linehan, M., Parkinson, D., deWolf, W., and Belldegrun, A. Renal cell carcinoma: recent progress and future directions. Cancer Res. 57: 5189-5195, 1997.
4. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet, 346: 336-340, 1995.
5. 131-anti-B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol., 14: 1974-1981, 1996.
6. Juweid, M., Sharkey, R. M., Markowitz, A., Behr, T., Swayne, L. C., Dunn, R., Hansen, H. J., Shevitz, J., Leung, S. O., Rubin, A. D., Herskovic, T., Hanley, D., and Goldenberg, D. M. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric or humanized LL2, an anti CD-22 monoclonal antibody. Cancer Res., 55: 5899s-5907s, 1995.
7. Wilder, R. B., Denardo, G. L., and Denardo, S. J. Radioimmunotherapy: recent results and future directions. J. Clin. Oncol., 14: 1383-1400, 1996.
8. Oosterwijk, E., Bander, N. H., Divgi, C. R., Welt, S., Wakka, J. C., Finn, R. D., Carswell, E. A., Larson, S. M., Warnaar, S. O., Fleuren, G. J., Oettgen, H. F., and Old, L. J. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J. Clin. Oncol., 11: 738-750, 1993.
9. Steffens, M. G., Boerman, O. C., Oosterwijk-Wakka, J. C., Witjes, J. A., Koenders, E. B., Oyen, W. J. G., Buijs, W. C. A. M., Debruyne, F. M. J., Corstens, F. H. M., and Oosterwijk, E. Targeting of renal cell carcinoma with iodine-131 labeled chimeric monoclonal antibody G250. J. Clin. Oncol., 15: 1529-1537, 1997.
10. Divgi, C. R., Bander, N. H., Scott, A. M., O'Donoghue, J. A., Sgouros, G., Welt, S., Finn, R. D., Morrissey, F., Capitelli, P., Williams, J. M., Deland, D., Nakhre, A., Oosterwijk, E., Gulec, S., Graham, M. C., Larson, S. M., and Old, L. J. Phase I/II radioimmunotherapy with iodine-131 labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin. Cancer Res., 4: 2729-2739, 1998.
11. Oosterwijk, E., Ruiter, D. J., Hoedemaker, P. J., Pauwels, E. K., Jonas, U., Zwartendijk, J., and Warnaar, S. O. Monoclonal antibody G250 recognizes a determinant present in renal cell carcinoma and absent from normal kidney. Int. J. Cancer, 38: 489-494, 1986.
12. Velders, M. P., Litvinov, S. V., Warnaar, S. O., Gorter, A., Fleuren, G. J., Zurawski, V. R., Jr., and Coney, L. R. New chimeric anti-pancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency. Cancer Res., 54: 1753-1760, 1994.
13. Oosterwijk, E., and Debruyne, F. M. Radiolabeled monoclonal anti-body G250 in renal-cell carcinoma. World J. Urol., 13: 186-190, 1995
14. Oosterwijk, E., de Weijert, M., van Bokhoven, A., Brakenhoff, R. H., Peelen, W. P., and Debruyne, F. M. J. Molecular characterization of the renal cell carcinoma associated antigen G250. Urol. Res., 23: 253, 1995.
15. Fraker, P. J., and Speck, J. C. Protein and cell membrane iodination with a sparingly soluble chloramide 1,3,4,6-tetrachloro-3,6-diphenylglucoril. Biochem. Biophys. Res. Commun., 80: 849-857, 1978.
16. Weadock, K. S., Sharkey, R. M., Varga, D. C., and Goldenberg, D. M. Evaluation of a remote radioiodination system for radioimmunotherapy. J. Nucl. Med., 31: 508-511, 1990.
17. Ebert, T., Bander, N. H., Finstad, C. L., Ramsawak, R. D., and Old, L. J. Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res., 50: 5531-5536, 1990.
18. Boerman, O. C., Tibben, J. G., Massuger, L. F., Claessens, R. A., and Corstens, F. H. Tumour targetting of the anti-ovarian carcinoma X anti-CD3/TCR bispecific monoclonal antibody OC/TR and its parental MOv18 antibody in experimental ovarian cancer. Anticancer Res., 15: 2169-2174, 1995.
19. Uemura, H., Okajima, E., Debruyne, F. M., and Oosterwijk, E. Internal image anti-idiotype antibodies related to renal cell carcinoma-associated antigen G250. Int. J. Cancer, 56: 609-614, 1994.
20. Wahl, R. L., Kroll, S., and Zasadny, K. R. Patient-specific whole body dosimetry: principles and a simplified method for clinical implementation. J. Nucl. Med., 39: 14s-20s, 1998.
21. Buijs, W. C., Oyen, W. J., Dams, E. T., Boerman, O. C., Siegel, J. A., Claessens, R. A., van der Meer, J. W., and Corstens, F. H. Dynamic distribution and dosimetric evaluation of human non-specific immunoglobulin G labelled with 111In or 99Tcm. Nucl. Med. Commun., 19: 743-751, 1998.
22. Stabin, M. G. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J. Nucl. Med., 37: 538-546, 1996.
23. 131I-labeled chimeric mouse/human IgG1, k 17-1A monoclonal antibody. J. Nucl. Med., 32: 1162-1168, 1991.
24. Buist, M. R., Kenemans, P., van Kamp, G. J., and Haismam, H. J. Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays. Cancer Immunol. Immunother., 1: 24-30, 1995.
25. 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Cancer Res., 55: 5916s-5920s, 1995.
26. Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Badger, C. C., Nelp, W. B., Glenn, S., Butchko, G., Fisher, D., Porter, B., Matthews, D. C., Fischer, L. D., and Bernstein, I. D. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med., 329: 1219-1224, 1993.